Clinical Trial Update: A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial comparing GDC-0810 with fulvestrant in postmenopausal women with advanced/metastatic breast cancer resistant to aromatase inhibitors; study termin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• GDC-0810

Snippet

Sponsor: Genentech, Inc. | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2021-04-23